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ABSTRACT
Development and validation of robust molecular biomarkers has so far been 
limited in melanoma research. In this paper we used a large population-based 
cohort to replicate two published gene signatures for melanoma classification. We 
assessed the signatures prognostic value and explored their biological significance 
by correlating them with factors known to be associated with survival (vitamin 
D) or etiological routes (nevi, sun sensitivity and telomere length). Genomewide 
microarray gene expressions were profiled in 300 archived tumors (224 primaries, 
76 secondaries). The two gene signatures classified up to 96% of our samples and 
showed strong correlation with melanoma specific survival (P=3x10-4), Breslow 
thickness (P=5x10-10), ulceration (P=9.x10-8) and mitotic rate (P=3x10-7), adding 
prognostic value over AJCC stage (adjusted hazard ratio 1.79, 95%CI 1.13-2.83), as 
previously reported. Furthermore, molecular subtypes were associated with season-
adjusted serum vitamin D at diagnosis (P=0.04) and genetically predicted telomere 
length (P=0.03). Specifically, molecular high-grade tumors were more frequent in 
patients with lower vitamin D levels whereas high immune tumors came from patients 
with predicted shorter telomeres. Our data confirm the utility of molecular biomarkers 
in melanoma prognostic estimation using tiny archived specimens and shed light on 
biological mechanisms likely to impact on cancer initiation and progression.
INTRODUCTION
Considerable efforts have been devoted to 
improving estimation of cancer prognosis with varying 
levels of successes. For melanoma, the American Joint 
Committee on Cancer (AJCC) proposed a staging system 
based on data from 31,000 melanoma patients [1]. This 
powerful tool uses histopathological features such as 
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Breslow thickness, presence of microscopic ulceration 
and mitotic rate that are robust markers of survival, as 
well as the result of sentinel node biopsy (presence of 
micrometastases in the sentinel node). Yet, the proportion 
of the variance in survival explained by the AJCC staging 
is still suboptimal, with a Receiver Operator Area Under 
the Curve (AUC) (i.e. proportion of the variance in 
survival explained by the system) of 74% [2]. 
Tumor derived gene and microRNA expression 
profiles have been explored as independent prognostic 
biomarkers in many cancers, for example breast 
cancer, colorectal cancer and nasopharyngeal cancer 
[3-5]. However, melanoma is very heterogeneous [6] 
and primaries are small, challenging the collection of 
adequate RNA sampling for inclusion in gene expression 
studies. A review of published melanoma biomarker 
reports highlighted a paucity of sufficiently powered 
and well-designed gene expression studies. However, 
the few that were compliant with REMARK (REporting 
recommendations for MARKer prognostic studies [7]) 
showed the ability of expression signatures to reproducibly 
predict melanoma prognosis, particularly the most 
advanced tumors [8, 9]. It was suggested that elucidation 
of the translational value of these gene signatures requires 
more research using larger datasets with well-annotated 
risk factors [8]. 
Jonsson and colleagues [10] generated a gene 
signature using 57 stage IV melanomas which they 
validated in a Swedish cohort of 223 primaries using 
the cDNA-mediated Annealing, Selection, Ligation 
and extension (DASL) [11], a technology designed for 
use with denatured RNA from formalin fixed paraffin 
embedded (FFPE) tumors [12]. A signature of 503 
genes defined 4 molecular classes, which were labeled 
as “proliferative”, “pigmentation”, “high immune” and 
“normal-like” reflecting characteristics most notable in 
terms of gene expression differences between the classes. 
This signature was subsequently refined to 2 major disease 
subtypes, the “high” and “low” grade, using a larger 
signature of 1864 genes [11]. These signatures have not 
yet been independently replicated in a population cohort. 
Molecularly defined high grade tumors were then 
shown to be thicker, more mitogenic and more frequently 
ulcerated, all of which are characteristic of poor prognosis. 
Both the 4-class and the 2-grade categorization defined 
on the basis of gene expression showed association 
with prognosis. In multivariable analyses, AJCC stage 
and molecular grade retained an independent significant 
prognostic value [11]. There was also an indication that 
low-grade melanomas were more likely to carry BRAF 
mutations while high-grade tumors were more likely to 
carry NRAS mutations although this subset analysis was 
based on a small number of tumors [11]. This molecular 
classification of melanoma appeared therefore to be 
potentially a valuable tool for understanding the disease 
biology using FFPE tumor samples and for clinical 
translation. 
The overall aim of the work described here is 
to assess the relevance of the two and four melanoma 
subtypes gene signatures developed in a Swedish cohort 
[11] in a well-annotated, population-based study from the 
North of England and to seek further evidence that these 
classes are meaningful by relating them to further patient 
and tumor characteristics. Specific aims were firstly to 
replicate these gene signatures in an independent large 
sample set, and secondly, to assess the added prognostic 
value. 
The description by Jonsson et al. [10, 11] of a 
4-class gene signature associated with biological pathways 
such as proliferation and immune reactions was of note. 
We therefore also tested the association between this 
signature and characteristics of the melanoma patients that 
we have previously reported to be related to melanoma 
susceptibility pathways, namely telomere length predicted 
from inherited genetic variation (telomere length score) 
[13], number of melanocytic nevi [14, 15] and sun 
sensitivity score [16], to test the hypothesis that different 
“routes” to melanoma [17] may determine the nature of 
the tumor. We have also previously reported an association 
between the 25-hydroxyvitamin D2/D3 levels at diagnosis 
(henceforth referred as vitamin D) and outcome [18] and 
we therefore examined the different molecular tumor sub-
types in relation to vitamin D levels at time of recruitment 
into the Leeds Melanoma Cohort.
RESULTS
Quality Control
We performed mRNA expression profiling in 
357 achieved melanomas using whole genome DASL 
HT12 v4. This array has 29,354 annotated probes and 
after examination of those detected by each sample at 
pvalue<0.05 (median = 14,365, inter-quartile range 12,435 
– 15,059), we excluded samples detecting less than 10,000 
probes. The final dataset comprised 300 samples: 208 from 
LMC (204 primaries plus 4 metastases) and 92 from the 
Chemotherapy study (20 primaries plus 72 metastases). 
After data normalisation there was high correlation 
between technical replicates (median 0.97, interquartile 
range 0.93 – 0.99), notably higher than between non-
replicates (median 0.85, interquartile range 0.81-0.88). 
We aimed to classify these samples using gene signature 
centroids developed in the Swedish cohort of primary 
tumors assayed on an earlier version of DASL array (HT8 
v3) and that had been filtered during QC to retain 8932 
best performing probes [11]. In the present study we have 
kept all 29,354 probes of the HT 12 v4 array in order to 
maximize the overlap between probe lists across the two 
datasets. After merging the probe lists, the overlap was 
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449/503 (89%) for the 4-class signature and 1584/1864 
(85%) for the 2-grade signature. The overlapping probes 
formed the basis of classification into the 4 category and 
2 category schemes.
Signature replication and association with 
histology 
Demographical and histological data are shown 
in Supplementary Table S1. All but 4 tumors in the 
LMC were primaries while 78% were secondaries from 
the Chemotherapy study. Because of this difference 
between studies, we present the signature replication in 
the two datasets separately and combined. Overall, the 
4-class signature classified 70 samples as high immune 
(correlation mean = 0.37, range: 0.12-0.74), 75 as normal-
like (correlation mean = 0.43, range: 0.11-0.70), 106 as 
pigmentation (correlation mean = 0.32, range: 0.10-0.62) 
and 37 as proliferative (correlation mean = 0.32, range: 
0.14-0.62) while 12 (4.0%) were not classifiable (highest 
correlation to any centroid: 0.03-0.10) (Supplementary 
Table S2). There was no difference between LMC and 
Chemotherapy Study in terms of the samples’ correlation 
with the centroids (Table S2). 
Figure 1A depicts the molecular classes identified as 
Figure 1: A. Full dataset classification using the 4-class signature and Kaplan-Meir survival curves using primary tumors from LMC 
(melanoma specific and relapse free survival). HI=high immune, NL=normal-like, PG=pigmentation, PRF=proliferative group. B. Full 
dataset classification using the 2-grade signature and Kaplan-Meir survival curves using primary tumors from LMC (melanoma specific 
and relapse free survival). Green = downregulation, red=upregulation.
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Figure 2: Top panel: Melanoma specific survival of patients with primary tumors from the two datasets. Bottom panel: 
Melanoma specific survival of all patients (primary and metastatic tumors) in the two datasets. Left and right respectively for the 4-class 
and the 2-grade signatures. HI=high immune, NL=normal-like, PG=pigmentation, PRF=proliferative group.
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a heatmap. As reported previously [10, 11], genes such as 
MITF and TYR are highly expressed in the pigmentation 
class, KRT10 and KRT17 in the normal-like class, IRF8 
and VCAM1 in high-immune tumors. Similarly, our data 
strongly suggested that patients with tumors that exhibit a 
particular molecular subtype have equally distinct survival 
profiles (Figures 1A). The patients with tumors classified 
in normal-like or high immune showed significantly 
better outcome than those classified as proliferative 
or pigmentation subtypes. Our data also demonstrated 
that only 2.7% of tumors classified as normal-like 
were metastatic compared to 54% of those classified as 
proliferative (Supplementary Table S3). There was no 
difference in survival patterns when the analysis was 
restricted to primary tumors from LMC, to all primaries 
from both datasets or all primaries and metastatic tumors 
combined (Figure 2). In addition, our data confirmed 
that the molecular subtypes are strongly correlated 
with AJCC stage (P=2.4 x 10-5) and 3 of its histological 
features: Breslow thickness (P= 2.4 x 10-9), microscopic 
ulceration (P=3.0 x 10-6) and mitotic rate (P=2.5 x 10-5) 
(Table 1). These results did not change when LMC and 
chemotherapy data were pooled (Supplementary Table 
S3).
The 2-grade signature identified 135 samples as high 
grade (correlation mean = 0.29, range: 0.10 – 0.59), 108 
as low grade (correlation mean = 0.34, range: 0.10 – 0.70) 
and 57 (19.0%) were unclassified (highest correlation 
range to any centroid: 0.0 – 0.10) (Supplementary Table 
S2). As expected, the vast majority of normal-like and 
high-immune tumors were low-grade (90%) while all 
proliferative and pigment-driven tumors were high 
grade (100%). Genes such as CCL21 and CXCL12 are 
characteristic of the low-grade while BRCA1, CDK4 and 
CDK6 are markers of the high-grade tumors (Figure 1B). 
As with the 4-class signature, the high- and low-grade 
delineation was correlated with AJCC staging (P=6.1x 10-
9), Breslow thickness (P=4.6x 10-10), presence of ulceration 
(P=8.9 x 10-8) and mitotic rate (P= 2.5 x 10-7) (Table 1). 
High-grade tumors were more likely to be metastatic than 
low-grade tumors (P=7.3 x 10-4, supplementary Table 
S3). Older patients were more likely to have a high-grade 
disease (P=0.01) while there was no relationship with 
sex (P=0.3) (Table 1). Patients with high- or low-grade 
molecular subtypes demonstrated different melanoma 
specific (MSS) and relapse-free survival (RFS) profiles: 
this was clearly apparent when the analysis was restricted 
to primary tumors from LMC (Figure 1B), to all primaries 
from both datasets or pooled primaries and metastatic 
tumors (Figure 2).
In melanoma specific survival analysis adjusting for 
AJCC stage and molecular grade, both predictors showed 
a strong effect (increasing AJCC HR=2.07, 95%CI 1.40 – 
3.06, P=0.0003; molecular grade HR=1.79, 95%CI=1.13 
– 2.83, P=0.01). In a multivariable model extended to 
other risk factors, molecular grade (HR=1.75, 95% CI 
1.12 – 2.75, P=0.01), increasing AJCC stage (HR=1.88, 
95% CI=1.26-2.83, P=0.002), presence versus absence 
of vascular invasion (HR=2.44, 95% CI=1.36-4.37, 
P=0.003) and primary tumor site on the limb vs. the rest 
of the body (HR=0.53, 95% CI=0.34-0.84, P=0.007) 
retained an independent effect. Supplementary figures 
S1–S3 illustrate that when survival analysis is stratified on 
Breslow thickness AJCC staging, mitotic rate, ulceration, 
sex, site and age at diagnosis, the molecular grade remains 
a powerful prognostic tool in each data subset.
Area under the ROC curves
The areas under the ROC curve (AUC) are shown in 
Table 3 and Figure 3. The AJCC stage has a higher AUC 
than the molecular grade and when they are combined 
their AUC reached 0.68 for relapse, 0.72 for death from 
melanoma and 0.78 for all deaths. The molecular grade 
increased the AUC by 3%-4% compared to AJCC stage 
alone and this improvement was significant for all deaths 
and for death from melanoma (one sided P=0.01 and 0.005 
respectively). Inclusion of other risk factors in the model 
(age, sex, the degree of tumor infiltrating lymphocytes, 
BRAF/NRAS mutation status and tumor regression) did 
not result in an increase of the AUC. Despite having an 
Oncotarget6www.impactjournals.com/oncotarget
independent association with outcome, vascular invasion 
and tumor site were omitted from ROC analyses due to a 
large proportion of missing records. 
Association between molecular subtypes and 
additional phenotypes
In the LMC, the 4-class signature showed an 
association with germline telomere length score, 
specifically with the high immune tumors having scores 
more predictive of shorter telomeres (p=0.03, Table 2). 
Although not significant there was also a substantial 
difference in nevus counts between molecular classes, 
with the high immune group having on average more than 
twice the number of nevi observed in the proliferative 
group (50 vs. 22, Table 2). The high/low molecular grade 
was marginally associated with season-adjusted vitamin 
D (p=0.04): primary tumors from patients with the lowest 
level of vitamin D at diagnosis were more likely to be 
of high grade (Table 2). Although vitamin D was not 
significantly different between the tumor subtypes defined 
by the 4-class signature (p=0.15), tumors in the high 
immune group showed notably the highest levels while 
the pigmentation group showed the lowest levels.
DISCUSSION
The prognosis for stage IV melanoma remains very 
poor but at last targeted therapies have been shown to 
have survival benefit [19, 20]. In those treated with the T 
cell checkpoint inhibitor ipilimumab, approximately 21% 
of patients survive in the very long term and checkpoint 
inhibiting PD-1 antibody nivolumab recently demonstrated 
a 30% increase of 1-year survival rate compared to DTIC 
in BRAF wild-type advanced melanoma patients [21]. 
However, Ipilimumab and other immune cell re-activators 
are associated with considerable toxicity compounded 
by the fact that patients may require several months of 
treatment before benefit is seen. There is therefore a 
great need to identify biomarkers, which predict benefit 
from such novel therapies. There is currently no adjuvant 
therapy conferring a survival benefit at acceptable toxicity. 
However, the rapid progress being made in the treatment 
of stage IV disease suggests that adjuvant therapies will 
improve, and better estimates of prognosis and molecular 
Table 3: Area under ROC curves in the full dataset 
Factor Relapse Deaths from melanoma All deaths
AJCC stage 0.657 0.681 0.754
Molecular grade 0.612 0.646 0.643
AJCC stage + molecular grade 0.683 a 0.718 a 0.782 a
a: Compared to AJCC stage alone, one-sided significance Pvalue=0.06 for relapse, 0.005 for melanoma-
caused deaths and 0.01 for all deaths. 
Figure 3: Area under the ROC curves for relapse, death from melanoma and all-causes death.
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subtypes will also be needed to aid patient selection for 
such therapies. Current methods of classifying melanoma 
rely upon histological examination and specific gene 
mutation testing. It has been recently suggested that the 
addition of molecular profiling will allow the identification 
of tumor sub-types possessing both prognostic and 
predictive significance [22]. The identification of 
reproducible molecular subtypes is therefore crucial as we 
move forward into a new therapeutic era. 
In this paper we report an independent replication 
of a published melanoma gene expression signature [11] 
using data generated from FFPE primary and metastatic 
melanomas. To our knowledge our data provide a first 
replication of this signature in a different population. The 
centroids derived from the Swedish cohort [11] allowed 
classification of 96% of our samples with the 4-class 
signature and 81% with the 2-grade signature. High-grade 
tumors are either more proliferative or driven by pigment-
related genes while low-grade tumors are characterised by 
a high immune activity or a dominance of stromal cells 
[11]. As in the Swedish cohort, molecular tumor subtypes 
were not only correlated with patient survival (Figure 1) 
but also with the main histopathological characteristics 
of melanoma: AJCC stage, Breslow thickness, mitotic 
rate, microscopic ulceration and patient age at diagnosis 
(Tables 1 and S3). Consistent with the Swedish study [11], 
the molecular grade retained an independent prognostic 
value in multivariable survival analysis. Our ROC analysis 
confirmed this added prognostic value with modest but 
significant increase in the AUC, confirming the well-
known high potency of the AJCC system for melanoma 
(which is notably higher than that of TNM staging of 
other cancers, see e.g. [2-4]) but also the potential for its 
improvement. 
Historically, it has proved difficult to replicate a 
number of gene expression signatures due to unreliability 
of early array technologies, disease heterogeneity, different 
sample collection methods or bias in the analyses [23]. 
Despite the known heterogeneity of melanoma [6] and 
the exclusive use of FFPE tissue, our study shows that 
advances in transcriptomic assays now allow molecular 
profiling to be replicated across samples from different 
populations, in both primary and metastatic tumors. We 
would propose however, that this replication is only an 
initial step and that by carrying out similar studies in larger 
data sets and by incorporating measures such as driver 
mutation status, gene signatures will be improved. It is 
the main strength of our sample set that the majority of 
tumors are population-ascertained (and therefore robust 
to selection bias) and accompanied by a rich record of 
phenotypes and genomewide germline genotypes.
It has been suggested that there are different 
etiological routes to melanoma related to clinical evidence 
of chronic sun damage (solar keratosis) or large numbers 
of nevi [17]. We sought to investigate whether particular 
molecular subtypes were common to patients with 
characteristics reflecting pathogenic routes to melanoma. 
Although we noted no associations between the molecular 
subtypes and sun sensitivity scores derived from hair, eye 
and skin color, nor with nevus count, we did demonstrate a 
statistically significant relationship between high immune 
tumors and a germline-derived polygenic telomere 
length score. It is intriguing to note that those tumors 
with a predominantly immune gene expression profile 
(with better survival) demonstrated shorter telomeres 
in peripheral blood samples. This finding and published 
evidence that genetically predicted shorter telomeres 
decrease melanoma risk [13] suggest a protective role of 
short telomeres for disease etiology and progression. 
It is noteworthy that several studies have 
demonstrated telomere shortening in subjects with 
reciprocal reduced long-term immune functioning [24, 
25]. Contrasting observations may reflect a fundamental 
difference in the immunogenicity of melanoma and of 
the individual tumor sub-types. We hypothesise that in 
patients whose tumors elicit a long-term immune reaction 
(thereby resulting in a potentially improved prognosis); we 
would also expect to see indications of decline in immune 
response in the form of leukocyte telomere erosion. 
Contrasting results of telomere length effect on cancer 
are also common in etiological studies. The increased risk 
to melanoma and nevi from longer telomeres has been 
attributed to delayed melanocytes senescence [26], which 
increases the chance of mutations in the oncogenic BRAF 
gene [27]. Our data must be viewed as preliminary and will 
be explored in large samples sets. However, the potential 
to predict telomere length based on molecular stratification 
of tumors is of clinical importance: longer telomeres were 
shown to predict the sensitivity of metastatic colorectal 
cancer to cetuximab, an anti-epidermal growth factor 
receptor (EGFR) drug [28]. 
We also tested the relationship between tumor 
molecular subtypes and season-adjusted vitamin D levels 
at diagnosis. We found that patients with the lowest levels 
of vitamin D at recruitment have high-grade tumors and, 
coincidentally, a worse prognosis (Table 2), supporting 
the view that vitamin D deficiency might be intrinsically 
linked to melanoma aggressiveness; although these 
observations do not demonstrate causality and must be 
tempered by previous reports that vitamin D levels are 
higher in fitter, leaner, healthier people and thus the low 
vitamin D levels noted in a spectrum of medical conditions 
may be merely acting as a proxy marker of health. 
In conclusion, our data provide a first independent 
validation of previously published melanoma gene 
signatures and confirm transcriptomic profiling as 
a valuable biomarker discovery tool for stratified 
medicine. The associations between disease subtypes 
with telomere length and vitamin D open up new avenues 





Investigation was conducted in accordance with 
the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and was approved by the authors’ institutional 
review board.
Study cohorts
Genome-wide gene expression profiles were 
generated in 357 FFPE tumor blocks from two studies. 
The first set of 231 were from the Leeds Melanoma 
Cohort (LMC, ethical approval MREC 1/3/57, PIAG 
3-09(d)/2003) comprised of 2184 population ascertained 
melanoma participants recruited in the North of England 
since 2000 (median follow up now 8 years) [29-31]. The 
primary tumors studied from LMC were not selected 
in that they were the first samples traced and sampled 
to date. The remaining set of 126 samples was from 
the Leeds Chemotherapy study (ethical approval 10/
H1313/72), which predominantly contains patients with 
advanced disease from across Europe. The FFPE blocks 
were sampled horizontally through the most invasive 
component of the tumor using a 0.6mm Tissue Micro 
Array (TMA) needle as previously described [29]. 
Sampling was only performed in those cases where 
sufficient tumor could be retained within the block after 
sampling, for future clinical testing. 
Detailed histological data were available for both 
sample sets, derived from the patients’ medical records, 
whilst for those generated from within the LMC more 
extensive data were available including patient peripheral 
blood-derived data, such as vitamin D levels measured in 
a serum sample collected at recruitment using methods 
described previously [18] and a telomere length score 
derived from 7 germline Single Nucleotide Polymorphism 
(SNP) genotypes associated with measured telomere 
length and previously shown to be associated with risk of 
melanoma in the general population; increased telomere 
score implies longer predicted telomere length and 
increased risk of developing melanoma in the general 
population [13]. In addition patient questionnaire data 
were available, including the number of melanocytic nevi 
2mm or larger in diameter, a sun sensitivity score derived 
from factor analysis of hair color, eye color, freckling in 
childhood, propensity to burn, ability to tan and skin color 
on the inside upper arm [16].
Gene expression data production
The mRNA was extracted from the tumor cores 
following a previously described protocol [29-31] and 
whole genome gene expression was quantified using the 
Illumina DASL Human HT12 v4 array. Samples were run 
in 3 batches and for quality control (QC) purposes, 3 cell 
lines, 5 control RNAs and 115 technical replicates were 
added to make a total of 480 arrays across the 3 batches. 
Gene expression data normalisation and quality 
control
Illumina’s GenomeStudio software was used to 
extract raw data from the image files. In our previous 
analysis of DASL data the number of transcripts detected 
per sample was a strong indication of the sample quality 
[29-31] and accordingly we excluded samples in which a 
low number of transcripts were detected. Remaining data 
were background-corrected and quantile-normalised using 
the package Lumi in R [32]. Normalised full intensity 
plots and boxplots were examined and the correlations 
between replicates were compared to non-replicates to 
assess array performance. Among technical replicates 
we then excluded the sample with the lowest number of 
probes detected. 
Replication of the four-class and two-grade gene 
signature 
We used the nearest centroid correlation approach 
to classify our samples, applying the 4-class and 2-grade 
centroids from the Swedish cohort of primary tumors 
(training set) [11]. Each centroid is a vector of average 
expressions of samples from the training dataset classified 
into a particular group (high immune, normal-like, 
pigmentation and proliferative for the 4-class signature; 
high and low grade for the 2-grade signature). Four-class 
centroids contain one average value for each of the 503 
genes while 2-grade centroids contain one average value 
for each of the 1864 genes. Each sample was classified 
separately into (a) one class and (b) one grade by 
calculating its correlation coefficient with the centroids and 
allocating the sample to class and grade to which it was 
the most correlated. A minimum correlation coefficient 
of 0.10 was required for successful classification, as in 
the Swedish study. Hierarchical clustering was applied to 
graphically represent the identified groups using Cluster 
3.0 and Java TreeView [33, 34].
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Association between disease subtypes, 
histopathological variables and other phenotypes
After sample classification into classes and grades 
we tested the correlation between the defined tumor 
subtypes, histopathological characteristics, relapse-free 
survival (RFS) and melanoma-specific survival (MSS). 
Pearson chi-square and Fisher Exact tests were applied to 
categorical variables; Mann-Whitney and Kruskall-Wallis 
tests were applied to continuous variables, Kaplan-Meier 
plots and log-rank tests were used in univariable survival 
analysis. The Cox proportional hazard model was applied 
to multivariable survival analysis adjusting for AJCC stage 
as a replication of previous reports [11] and with other 
histological variables. These analyses were conducted in 
STATA v12 (StataCorp, Texas, USA).
Area under the Receiver Operator Curves (ROC)
The area under the ROC curves (AUC) was 
estimated in a logistic regression model predicting 
relapse, all-cause death and death from melanoma. 
Univariate AUC was computed for each risk factor and a 
multivariable AUC was computed in a model that included 
AJCC stage, molecular grade and traditional risk factors. 
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